Merz Therapeutics tests the long game in neurorehabilitation with XEOMIN data
Spasticity care is not one injection cycle. Merz Therapeutics is pushing XEOMIN data toward durability, dosing flexibility and patient goals.
Pharma & Biotech
Medical Devices & Diagnostics
Merz Therapeutics files XEOMIN pediatric spasticity indication with EMA following Phase 3 success
Merz Therapeutics files EMA application to expand XEOMIN for pediatric spasticity. Find out how this could shift the treatment landscape for cerebral palsy.